Cipher Pharmaceuticals Inc.   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Mississauga ON Canada (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2009
NCT00975143
First Marketed Drug
2006
fenofibrate (fenoglide)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CIPHER PHARMS INC | Halodine LLC

Active Ingredients

Marketed Drugs (2)

fenofibrate (fenoglide) (2006)

tramadol (Ultram) (2010)

Drugs in Phase 4 Trials (1)

povidone-iodine (betadine) (1 trial)

Drugs in Phase 3 Trials (1)

isotretinoin (Accutane) (1 trial)

Drugs in Phase 1 Trials (2)

moxifloxacin (avelox) (1 trial)

tramadol (Ultram) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4